pharma · Kidney Dysfunction · Obesity
LianBio
Jian Li
LianBio trial registry — 28 ClinicalTrials.gov studies with program phase, status, and indication context.
CN HQ
2019 Founded
47 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Founded
- 2019
- Employees
- 47
- Programs
- 28
- Drugs
- 40
- Patents
- 0
LianBio clinical trials
Registry index of 28 ClinicalTrials.gov studies linked to LianBio programs — each row shows trial ID, program name, phase, status, and indication.
LianBio trial registry — 28 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for LianBio.
-
Radiotherapy combined with TKI and Anti-PD-1 Antibody — Unknown
Clinical update -
Placebos — Phase 3
Clinical update -
Part1:Recombinant two-component COVID-19 vaccine (CHO cell) — Phase 2
Clinical update -
Karelizumab combined with etoposide and cisplatin — Phase 2
Clinical update -
Irinotecan liposome、5-Fluorouracil、Leucovorin — Phase 3
Clinical update -
HS-10382(Part 1: Dose escalation) — Phase 1
Clinical update -
High-Low Dose Radiotherapy — Phase 2
Clinical update -
GST-HG121 tablets — Phase 1
Clinical update
Trial registry
-
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ - NCT05074589CT.gov ↗
Irinotecan liposome、5-Fluorouracil、Leucovorin
Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy
-
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ - NCT06061445CT.gov ↗
Radiotherapy combined with TKI and Anti-PD-1 Antibody
Stage IIIA Hepatocellular Carcinoma
-
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗